Peer review process
Not revised: This Reviewed Preprint includes the authors’ original preprint (without revision), an eLife assessment, and public reviews.
Read more about eLife’s peer review process.Editors
- Reviewing EditorCaetano AntunesUniversity of Kansas, Lawrence, United States of America
- Senior EditorOlujimi AjijolaUniversity of California, Los Angeles, Los Angeles, United States of America
Reviewer #1 (Public Review):
Summary:
The authors aimed to identify potential biomarkers for acute myocardial infarction (AMI) through blood metabolomics and fecal microbiome analysis. They found that long chain fatty acids (LCFAs) could serve as biomarkers for AMI and demonstrated a correlation between LCFAs and the gut microbiome. Additionally, in silico molecular docking and in vitro thrombogenic assays showed that these LCFAs can induce platelet aggregation.
Strengths:
The study utilized a comprehensive approach combining blood metabolomics and fecal microbiome analysis.
The findings suggest a novel use of LCFAs as biomarkers for AMI.
The correlation between LCFAs and the gut microbiome is a significant contribution to understanding the interplay between gut health and heart disease.
The use of in silico and in vitro assays provides mechanistic insights into how LCFAs may influence platelet aggregation.
Weaknesses:
The evidence is incomplete as it does not definitively prove that gut dysbiosis contributes to fatty acid dysmetabolism.
The study primarily shows an association between the gut microbiome and fatty acid metabolism without establishing causation.
Reviewer #2 (Public Review):
Summary:
Fan et al. investigated the relationship between early acute myocardial infarction (eAMI) and disturbances in the gut microbiome using metabolomics and metagenomics analyses. They studied 30 eAMI patients and 26 healthy controls, finding elevated levels of long-chain fatty acids (LCFA) in the plasma of eAMI patients.
Strengths:
The research attributed a substantial portion of LCFA variance in eAMI to changes in the gut microbiome, as indicated by omics analyses. Computational profiling of gut bacteria suggested structural variations linked to LCFA variance. The authors also conducted molecular docking simulations and platelet assays, revealing that eAMI-associated LCFAs may enhance platelet aggregation.
Weaknesses:
The results should be validated using different assays, and animal models should be considered to explore the mechanisms of action.
